

Episode-of-care costs of total hip arthroplasty: day surgery versus same-day admission

Philippe Moisan, MD, MSc
 Julien Montreuil, MD, MSc
 Mitchell Bernstein, MD
 Adam Hart, MD, MSc
 Michael Tanzer, MD

Accepted June 13, 2022

Correspondence to:

J. Montreuil
 1650 Cedar Ave
 Montréal QC H3G 1A4
 julien.montreuil@mail.mcgill.ca

Cite as: *Can J Surg* 2023 February 2; 66(1). doi: 10.1503/cjs.000722

Background: Although day surgery (DS) total hip arthroplasty (THA) has good patient satisfaction and a good safety profile, accurate episode-of-care cost (EOCC) calculations for this procedure compared to standard same-day admission (SDA) THA are not well known. We determined the EOCCs for patients who underwent THA, comparing DS and SDA pathways.

Methods: We evaluated the EOCCs for consecutive patients who underwent DS or SDA THA for osteoarthritis or osteonecrosis performed by a single surgeon at 1 academic centre from July 2018 to January 2020. Patient demographic and clinical data were recorded, as were preoperative diagnosis, type of anesthesia, type of implant used, surgical time and estimated blood loss. We determined direct and indirect costs from time of arrival at the presurgical unit to hospital discharge. We determined the EOCCs using an ABC method.

Results: The study included 50 patients who underwent THA (25 DS, 25 SDA). The mean length of stay in the SDA group was 45.1 (standard deviation [SD] 21.4) hours. Differences were observed between the 2 groups in mean age, mean Charlson Comorbidity Index score, surgical technique and mean surgical time ($p \leq 0.001$). The mean total EOCC for SDA THA was \$10 911 (SD \$706.12, range \$9944.07–\$12 871.95), compared to \$9672 (SD \$546.55, range \$8838.30–\$11 058.07) for DS THA, a difference of 11.4%, mostly attributable to hospital resources such as laboratory tests, radiologic studies and cost of the surgical admission.

Conclusion: Day surgery THA is cost-effective in selected patient populations. With the savings identified in this study, every 10 additional DS THA procedures would save sufficient resources to perform an additional THA operation.

Contexte : Si l'arthroplastie totale de la hanche (ATH) en chirurgie d'un jour est associée à un taux de satisfaction élevé des patients et à un bon profil d'innocuité, il existe peu de calculs précis du coût de la période de traitement (CPT) pour cette intervention par rapport au coût des interventions avec hospitalisation. Nous avons déterminé le CPT des patients ayant subi une ATH pour ensuite comparer les interventions en chirurgie d'un jour à celles avec hospitalisation.

Méthodes : Nous avons évalué le CPT de patients consécutifs ayant subi une ATH en chirurgie d'un jour ou avec hospitalisation pour cause d'arthrose ou d'ostéonécrose auprès d'un même chirurgien dans un centre universitaire entre juillet 2018 et janvier 2020. Les caractéristiques démographiques et les données cliniques des patients ont été notées, de même que le diagnostic préopératoire, le type d'anesthésie, le type d'implant utilisé, le temps de chirurgie et la perte sanguine estimée. Nous avons déterminé les coûts directs et indirects, de l'admission à l'unité préopératoire jusqu'au congé de l'hôpital, et calculé le CPT avec la méthode des coûts par activités.

Résultats : L'étude comprenait 50 patients ayant subi une ATH (25 en chirurgie d'un jour, 25 avec hospitalisation). La durée de séjour moyenne pour le groupe en chirurgie d'un jour était de 45,1 heures (écart type [É.T.] 21,4 heures). Des différences ont été notées entre les 2 groupes pour l'âge moyen, l'indice de comorbidités de Charlson moyen, la technique chirurgicale et le temps de chirurgie moyen ($p \leq 0,001$). Le CPT total moyen était de 10911 \$ pour les interventions avec hospitalisation (É.T. 706,12 \$, plage 9944,07 \$–12 871,95 \$), comparativement à 9672 \$ pour les chirurgies d'un jour (É.T. 546,55 \$, plage 8838,30 \$–11 058,07 \$), une différence de 11,4 % attribuable principalement aux ressources hospitalières telles que les analyses de laboratoire, les examens radiologiques et les coûts d'admission au bloc opératoire.

Conclusion : L'ATH en chirurgie d'un jour est rentable lorsqu'on cible des populations de patients précises. Selon les économies quantifiées dans cette étude, les ressources économisées en réalisant 10 ATH en chirurgie d'un jour seraient suffisantes pour une intervention de plus.

Patients with end-stage hip osteoarthritis are commonly treated with total hip arthroplasty (THA). This operation has become one of the most successful and common orthopedic procedures, restoring function to more than 65 000 Canadians each year.¹ In recent years, there has been a shift toward outpatient surgery and shorter hospital stays for patients undergoing THA in order to accelerate patient recovery, but also to reduce health care costs.² A multimodal, interdisciplinary approach optimizing patient selection, preoperative planning, patient counseling, improved surgical techniques involving minimally invasive approaches, optimized perioperative analgesia and early postoperative mobilization has allowed day surgery (DS) THA to be done safely and with high patient satisfaction.³⁻⁹ In Canada, the average length of hospital stay for THA is 2.6 days.¹⁰ Four times as many joint replacement procedures were done as outpatient surgery in 2020–2021 compared to 2019–2020.¹⁰

On average, in 2019–2020 in Canada, inpatient hip replacement surgery had a mean estimated cost of \$9591 (estimated with a case-mix group methodology and including inpatient physician costs and excluding rehabilitation), for a total more than \$600 million spent annually on this procedure.¹⁰ Although DS has good patient satisfaction, the cost benefit of this procedure compared to standard same-day admission (SDA) is not well known. Despite the large impact of episode-of-care costs (EOCCs) for hospital stays on hospital budgets, accurate calculation of these costs remains a challenge in Canada. High-performing universal health care systems, such as those in Australia, France, Germany, the Netherlands, Sweden, Switzerland and the United Kingdom, use activity-based funding to remunerate hospitals.^{11,12} Current methodologies involve top-to-bottom approximation of costs through grouping systems and traditional accounting. Canadian provinces are also gradually transitioning toward more precise and tailored funding methods involving diagnostic-related groups and case-mix methodologies.¹³

To better describe EOCCs, activity-based costing (ABC) examines comprehensively all elements of a medical act to estimate costs and subsequent funding. The ABC methodology varies from traditional costing schemes in that calculations based on weighted resource use are utilized, rather than a top-down approximation system.¹² Those methodologies advance the understanding of the economic burden of different medical conditions and the source of cost variability through elaborated clinical and administrative data analysis.^{11,14-16}

Despite the emergence of ABC models, few investigators have successfully evaluated the EOCCs of orthopedic procedures such as THA.¹⁷⁻²⁰ Considering the increasing number of prosthetic joints and the substantial economic impact of THA, it is important to understand its EOCCs to provide policy-makers with the information necessary to develop optimal financing methods based on individual

patient complexity, which is paramount for the economic sustainability of our health care system.

The objective of this study was to determine the EOCCs using ABC methodology for patients who underwent THA, comparing DS and SDA (with a 2-d hospital stay) pathways.

METHODS

This was a retrospective cohort study of consecutive patients treated surgically with THA (cementless arthroplasty or hybrid THA) for osteoarthritis or osteonecrosis in an academic centre. All procedures were performed by a single surgeon (M.T., a fellowship-trained arthroplasty surgeon) at 1 institution from July 2018 to January 2020. All patients requiring simple, primary THA without associated bone graft or osteotomy were included. Patients older than 80 years were excluded, as were those with severe cardiovascular or pulmonary disease, liver cirrhosis, renal failure, type 1 diabetes or narcotic dependence, and those requiring revision arthroplasty, since they were not eligible for our institutional DS enhanced recovery pathway. The study was approved by our hospital ethics board.

Demographic characteristics

Patient demographic data, including age, gender, comorbidities, body mass index, American Society of Anesthesiologists classification and Charlson Comorbidity Index score, were recorded. The patients' charts were reviewed retrospectively to identify the preoperative diagnosis, type of anesthesia, type of implant used, surgical time and estimated blood loss. We defined postoperative length of stay as the number of days each patient spent on the wards after the surgical intervention.

Surgery and postoperative protocol

All patients had surgery under epidural or spinal anesthesia and received sedation based on their level of anxiety. Normothermia was maintained with a heated blanket. In all cases, a highly porous coated cementless acetabular implant with a highly cross-linked polyethylene liner was used. The choice of femoral implant was based on the patient's femoral morphology and bone quality.

All patients had portable anteroposterior pelvis radiography in the postanesthesia care unit (PACU) to ensure that the hip was reduced and there were no fractures. In addition, patients in the SDA group had anteroposterior and cross-table lateral hip radiography the day after surgery, before discharge. No patients had any routine blood tests in the PACU. Patients in the SDA group routinely had a complete blood count and electrolyte analysis performed on the day after surgery.

A perioperative pathway protocol²¹ was used in the DS group. The preoperative medications for both groups included orally administered acetaminophen, celecoxib, ondansetron and tranexamic acid.²¹ In addition, the patients on the DS pathway received controlled-release oxycodone and pregabalin and a scopolamine patch 1–2 hours before surgery. Patients in both groups received 2 g of cefazolin within 60 minutes before the incision was made. Two hours after surgery, patients were given 2 g of tranexamic acid orally. Postoperative instructions included weight bearing as tolerated, diet as tolerated, restricted adduction and posterior hip precautions. Four to 6 hours after surgery, patients were evaluated for discharge with the following criteria: must eat a meal before discharge, normotensive after orthostatic challenge, pain managed adequately, distal neurovascular status intact and clearance by a physiotherapist. All patients in the DS group were seen by a physiotherapist in the PACU 2–4 hours after surgery. Patients in the SDA group did not receive any physiotherapy until the next day, on the ward.

Patients in both groups received a second dose of 2 g of cefazolin 8 hours after the preoperative dose. Patients were discharged home with a prescription for acetaminophen, 650–1000 mg every 6 hours for 14 days, hydromorphone, 0.5–1.0 mg orally every 4–6 hours as needed, celecoxib, 100 mg orally twice a day for 10 days, and rivaroxaban, 10 mg orally once a day for 5 days followed by acetylsalicylic acid, 81 mg orally for 30 days.

Costing data

We determined direct and indirect costs from time of arrival at the presurgical unit to hospital discharge. Data were extracted with the PowerPerformance Manager (PPM) system (PowerHealth), a centralized database that is secured and managed by an institutional data warehouse. The PPM system enables prompt extraction of data including itemized direct and indirect costs per episode of care, procedure codes, adverse events and precise temporal data. The demographic characteristics were extracted manually from the institution electronic medical record system, OACIS (Telus Health).

The episode of care consisted of the surgical episode from arrival at the preoperative unit to discharge from the PACU for patients in the DS group and to discharge from the surgical ward for patients in the SDA group. Costs for the 6-week postoperative visit were also included. Itemized costs were extracted for each patient's perioperative EOCCs with the PPM software. These operational costs were classified as direct (clinician labour, equipment, implants, consumables and laboratory testing) or indirect (management, information technology, billing, logistics, sterilization, maintenance and human resources) (Box 1). The arthroplasty implants included the acetabular component, 2 acetabular screws, cross-linked polyethylene

Box 1. Direct and indirect costs for activity-based costing

Direct costing areas

- Operating room
- Postanesthesia care unit (recovery room)
- Surgical unit
- Laboratory testing
- Supply, implants and consumables
- Pharmacy
- Imaging
- Professional (occupational therapy/physiotherapy)
- Durable medical equipment
- Transport
- Emergency department
- Intensive care unit

Indirect costing areas

- Billing
- Information technology
- Central sterile processing
- Maintenance
- Human resources
- Hospital administration
- Nonclinical salaries

liner, femoral stem and ceramic femoral head. We calculated the costs associated with these consumables based on direct purchase price. All items, from the surgical gowns in the operating room (OR) to the cost of individual blood tests on the wards, were extracted, coded and linked to an encounter. All fixed and periodic costs of support resources necessary to supply a service or a procedure were included. Allocation of the indirect costing inputs to each surgical encounter followed an ABC framework as provided by governmental authorities. Areas of care received indirect costs following equations allocating the amount based on time spent on each activity. If time was not applicable (e.g., with consumables), we distributed indirect costs following ratios based out of use. We excluded physician remuneration from direct costs because these fees are borne by the provincial government and not the hospital.²²

Statistical analysis

The data were stored and analyzed via Prism version 9 software (GraphPad). We used unpaired Student *t* tests to compare outcomes between the DS and SDA groups. Statistical significance was set at $p < 0.05$ and confidence interval at 95%. Continuous variables were presented as mean and standard deviation (SD).

RESULTS

The study included 50 patients treated surgically with THA, 25 in the DS group and 25 in the SDA group. Cementless arthroplasty was done in 44 patients (88%), and 6 patients (12%) had hybrid THA. Differences were observed in mean age, mean Charlson Comorbidity Index score, surgical technique and mean surgical time between the DS and SDA groups (Table 1). The mean age was 71.1 (SD 10.0) years in the SDA group and 60.6 (SD 10.4) years in the DS group ($p < 0.001$). The mean Charlson Comorbidity Index score was 3.2 (SD 1.3) in the SDA group and 2.0 (SD 2.0) in the DS group ($p = 0.001$). Six

Table 1. Demographic and clinical characteristics of patients who underwent total hip arthroplasty with the same-day admission or day surgery pathway

Characteristic	No. (%) of patients*		p value
	SDA n = 25	DS n = 25	
Age, mean ± SD, yr	71.1 ± 10.0	60.6 ± 10.4	< 0.001
Gender			
Male	7 (28)	11 (44)	
Female	18 (72)	14 (56)	
Body mass index			
Mean	28.1 ± 6.6	29.1 ± 5.1	0.6
< 25	0 (0)	0 (0)	
25–29	0 (0)	0 (0)	
30–34	24 (96)	21 (84)	
≥ 35	1 (4)	4 (16)	
Anesthesia			
Spinal	20 (80)	20 (80)	
Epidural	0 (0)	2 (8)	
General	5 (20)	3 (12)	
ASA class			
1	0 (0)	5 (20)	
2	18 (72)	20 (80)	
3	6 (24)	0 (0)	
4	1 (4)	0 (0)	
Charlson Comorbidity Index score			
Mean	3.2 ± 1.3	2.0 ± 2.0	0.001
1	2 (8)	2 (8)	
2	5 (20)	5 (20)	
3	8 (32)	14 (56)	
4	6 (24)	2 (8)	
5	3 (12)	1 (4)	
6	1 (4)	1 (4)	
Side			
Left	12 (48)	12 (48)	
Right	13 (52)	13 (52)	
Technique			
Uncemented	19 (76)	25 (100)	
Cemented	6 (24)	0 (0)	
Surgical time, mean ± SD, min	113.0 ± 24.5	88.2 ± 13.5	< 0.001
LOS, mean ± SD, h	45.1 ± 21.4	—	—

ASA = American Society of Anesthesiologists; DS = day surgery; LOS = length of stay; SD = standard deviation; SDA = same-day admission.
*Except where noted otherwise.

patients (24%) in the SDA group had a cemented prosthesis, compared to no patients in the DS group. The mean surgical time was greater in the SDA group than in the DS group (113.0 [SD 24.5] min v. 88.2 [SD 13.5] min) (*p* < 0.001). The mean length of stay in the SDA group was 45.1 (SD 21.4) hours.

Episode-of-care costs

The mean total EOCC for SDA THA was \$10 911.12 (SD \$706.12) (range \$9944.07–\$12 871.95), compared to

\$9672.09 (SD \$546.55) (range \$8838.30–\$11 058.07) for DS THA, a difference of –\$1239.03 (11.4%) (*p* < 0.001) (Table 2).

The mean cost of implants was not significantly different between the DS and SDA groups (\$6011.38 [SD \$343.76], range \$5186.77–\$7015.98 v. \$6047.67 [SD \$481.09], range \$5128.62–\$7000.81) (*p* = 0.8) (Table 2). The mean OR operational cost for the DS group was \$1632.30 (SD \$158.55) (range \$1414.29–\$1958.25), compared to \$1860.34 (SD \$358.67) (range \$1396.49–\$3058.25) for the SDA group (*p* = 0.006). There was no significant difference in the mean per-patient PACU cost between the DS and SDA groups (\$712.99 [SD \$297.23], range \$135.42–\$1776.93 v. \$615.11 [SD \$211.13], range \$135.42–\$1167.53) (*p* = 0.2). The additional routine postoperative blood tests and the radiographs in the SDA group resulted in an extra cost of \$61.53 and \$27.85 per patient, respectively (Figure 1). The costs for postoperative physiotherapy, OR materials and the 6-week follow-up visit were identical for the 2 groups. All patients in the SDA group were discharged before or at postoperative day 2, and the cost of admission to the ward averaged \$946.12 (SD \$426.61) (range \$546.10–\$2366.88), 10% more than the cost to treat the patients in the DS group.

DISCUSSION

This study provides an in-depth analysis of the EOCCs associated with THA protocols in a Canadian academic centre. We used an ABC methodology to compare the 6-week cost of DS versus SDA THA. This methodology provides a precise analysis of both direct and indirect costs. In this study, the EOCC of DS THA was on average \$1239, or 11% less expensive than that of SDA THA. There are multiple factors that explain the difference in cost between the DS and SDA THA protocols, but the cost of the hospital admission was the main driver of the increased cost of SDA THA.

In addition to the mean daily fee of \$946 of the surgical nursing unit, an admission was associated with higher costs for laboratory tests and additional radiologic studies (mean \$89.30). Our DS protocol does not include any postoperative laboratory tests or additional radiographic imaging of the hip. Although these additional tests are commonly ordered as part of a routine admission protocol, it may be cost effective to consider individualizing this practice and testing only patients with suspected complications or underlying medical conditions that warrant close in-hospital follow-up.^{23,24} It is currently unknown what proportion of THA procedures in Canada are done as day operations. Assuming that 65 000 THA procedures are done every year, if 50% of those are done as DS procedures as opposed to all SDA procedures, this would allow savings of more than \$40 million.

Table 2. Episode-of-care costs

Costing area	Cost, \$				p value
	SDA		DS		
	Mean ± SD	Range	Mean ± SD	Range	
Implants	6047.67 ± 481.09	5128.62–7000.81	6011.38 ± 343.76	5186.77–7015.98	0.8
OR operational	1860.34 ± 358.67	1396.49–3058.25	1632.30 ± 158.55	1414.29–1958.25	0.006
OR material*	838.24	—	838.24	—	—
Postanesthesia care unit	615.11 ± 211.13	135.42–1167.53	712.99 ± 297.23	135.42–1776.93	0.2
Laboratories*	61.53	—	0.00	—	†
Pharmacy	186.89 ± 72.03	117.70–424.65	149.81 ± 78.86	43.14–269.68	0.09
Radiology*	83.00	—	0.00	—	—
Physiotherapy*	85.95	—	85.95	—	—
Surgical unit admission	946.12 ± 426.61	546.10–2366.88	0.00	—	†
6-wk postoperative visit*	187.29	—	187.29	—	—
Total	10 911.12 ± 706.12	9944.07–12 871.95	9672.09 ± 546.55	8838.30–11 058.07	< 0.001

DS = day surgery; OR = operating room; SD = standard deviation; SDA = same-day admission.
 *Fixed cost.
 †Direct significant difference given absence of cost.




Fig. 1. Same-day admission episode-of-care costs. OR = operating room; PACU = postanesthesia care unit.

Despite the higher comorbidity in the SDA group, there was no significant difference in pharmacy costs between the 2 groups. We calculated the OR cost based

on the time the room was used and the personnel present before, during and after the operation. One of the reasons explaining the increased OR costs in the SDA group is the difference in demographic characteristics between the 2 groups and the difference in implant fixation. It has been shown that patients with a higher Charlson Comorbidity Index score incur higher costs for THA.^{25,26} Patients selected for SDA were significantly older than those in the DS group and had a higher mean Charlson Comorbidity Index score, which can be associated with a more complex approach and a longer surgical procedure, and, therefore, a more expensive procedure. As well, 6 patients in the SDA group had a cemented femoral stem, compared to no patient in the DS group. Cementing and implanting a femoral stem takes more time than implanting a cementless stem, thereby contributing to the increased surgical time and, consequently, the increased OR costs in the SDA group. Although direct implant costs were not significantly different between the 2 groups, using the same implants (either all hybrid or uncemented) would tend to normalize surgical time between the groups and, by the same effect, OR cost. However, even when the implant and the other costs were equalized, admission to the ward on its own resulted in an increase of 10% in the cost of THA. The inherent differences between patients in the DS and SDA groups resulted in different medical comorbidity and implant profiles between the 2 groups; however, our cost analysis captures these differences. The surgeon and anesthesiologist fees for the surgery (about \$1000 and \$500, respectively) were not included in our cost analysis.

Other investigators have looked at the potential cost savings associated with DS THA. Venditoli and colleagues²¹ reported a reduction in hospital costs of \$1489 with DS compared to SDA THA, but they did not include the implant costs. Petis and colleagues²⁷ found that the cost in

Ontario of a 2-day hospital stay after THA was \$2727, compared to \$1239 for a 1-day stay. Using an ABC methodology, DiGioia and colleagues²⁸ estimated a mean cost of US\$11 319–US\$12 319 for SDA THA using an implant costing US\$4000–US\$5000. With a similar implant cost, and including the estimated surgeon and anesthetist fees, our estimated cost for SDA THA would be \$12 411 (US\$9814). Other studies have shown a reduction in total costs with outpatient THA in the United States of 16%–21%,^{29,30} compared to the 11% reduction in the present study.

Limitations

There are limitations of this study that can be addressed in future research. The small sample was susceptible to sampling bias and reduced the statistical power of the analysis. The patients in the SDA group were older than those in the DS group, with more comorbidities, which affected the surgical technique and choice of implant. However, not all patients are eligible for DS THA owing to their medical conditions. This study took this into account by recognizing the need to admit some patients undergoing THA, and the need to use a cemented femoral stem and perform postoperative blood tests in many of these patients. When we excluded the implants and tests, the cost of SDA THA was still 10% higher than that of DS THA. In addition, the enrolment of patients from a single hospital and single surgeon limits the generalizability of the results. However, institution-specific data should be encouraged to promote internal quality-improvement initiatives and interinstitution comparisons. Finally, the retrospective nature of the study may also be a potential source of selection bias in the composition of this cohort, although temporality was not an issue, given the nature of the primary outcome.

CONCLUSION

The mean total cost of SDA THA was \$10 911, compared to \$9672 for DS THA, a difference of 11%, mostly attributable to hospital resources such as laboratory tests, radiologic studies and cost of the surgical admission. With the savings identified in this study, every 10 additional DS THA procedures would save sufficient resources to perform an additional THA operation. The DS pathway was associated with superior postoperative functional outcomes compared to the SDA pathway. This value-based health care study provides evidence that DS THA is cost-effective when used with evidence-based perioperative interdisciplinary care pathways.

Acknowledgement: The authors thank the McGill University Health Centre cost analysts and Data Warehouse team for providing the data.

Affiliations: From the Faculty of Medicine, McGill University, Montréal, Que. (Moisan); and the Division of Orthopaedic Surgery, McGill University, Montréal, Que. (Montreuil, Bernstein, Hart, Tanzer).

Competing interests: Mitchell Bernstein reports consulting fees from Smith & Nephew, Orthofix, Restor3D and NuVasive. He sits on the Executive Board of the Limb Lengthening and Reconstruction Society. No other competing interests were declared.

Contributors: M. Bernstein, J. Montreuil and A. Hart designed the study. P. Moisan and M. Tanzer analyzed the data. P. Moisan and J. Montreuil wrote the manuscript, which M. Bernstein, A. Hart and M. Tanzer critically revised. All authors gave final approval of the article to be published.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. *Hip and knee replacements in Canada: CjRR annual report, 2020–2021*. Ottawa: Canadian Institute for Health Information; 2022 [updated September 2022].
2. Gogineni HC, Gray CF, Prieto HA, et al. Transition to outpatient total hip and knee arthroplasty: experience at an academic tertiary care center. *Arthroplast Today* 2018;5:100-5.
3. Cheng T, Feng J, Liu T, et al. Minimally invasive total hip arthroplasty: a systematic review. *Int Orthop* 2009;33:1473-81.
4. Khanna A, Gougoulias N, Longo U, et al. Minimally invasive total knee arthroplasty: a systematic review. *Orthop Clin North Am* 2009; 40:479-89.
5. Dorr LD, Thomas D, Zhu J, et al. Outpatient total hip arthroplasty. *J Arthroplasty* 2010;25:501-6.
6. Parcells BW, Giacobbe D, Macknet D, et al. Total joint arthroplasty in a stand-alone ambulatory surgical center: short-term outcomes. *Orthopedics* 2016;39:223-8.
7. Goyal N, Chen A, Padgett S, et al. Otto Aufranc Award: A multicenter, randomized study of outpatient versus inpatient total hip arthroplasty. *Clin Orthop Relat Res* 2017;475:364-72.
8. Berger RA, Jacobs J, Meneghini R, et al. Rapid rehabilitation and recovery with minimally invasive total hip arthroplasty. *Clin Orthop Relat Res* 2004;429:239-47.
9. Hoffmann JD, Kusnezov N, Dunn J, et al. The shift to same-day outpatient joint arthroplasty: a systematic review. *J Arthroplasty* 2018; 33:1265-74.
10. *Hip and knee replacements in Canada: CjRR quick stats, 2019–2020*. Ottawa: Canadian Institute for Health Information; 2021.
11. Akhavan S, Ward L, Bozic KJ. Time-driven activity-based costing more accurately reflects costs in arthroplasty surgery. *Clin Orthop Relat Res* 2016;474:8-15.
12. Heslop L. Activity-based funding for safety and quality: a policy discussion of issues and directions for nursing-focused health services outcomes research. *Int J Nurs Pract* 2019;25:e12775.
13. Mihailovic N, Kocic S, Jakovljevic M. Review of diagnosis-related group-based financing of hospital care. *Health Serv Res Manag Epidemiol* 2016;3:2333392816647892.
14. Kaplan RS, Anderson S. Time-driven activity-based costing. *Harv Bus Rev* 2004;82:131-8.
15. Kaplan R, Porter M. How to solve the cost crisis in health care. *Harv Bus Rev* 2011;89:46-52.
16. Sethi RK, Pumpian R, Drolet C, et al. Utilizing lean methodology and time-driven activity-based costing together: an observational pilot study of hip replacement surgery utilizing a new method to study value-based health care. *J Bone Joint Surg Am* 2021 Oct. 14 [Epub ahead of print]. doi: 10.2106/JBJS.21.00129
17. Palsis JA, Brehmer T, Pellegrini V, et al. The cost of joint replacement: comparing two approaches to evaluating costs of total hip and knee arthroplasty. *J Bone Joint Surg Am* 2018;100:326-33.

18. McCreary DL, White M, Vang S, et al. Time-driven activity-based costing in fracture care: Is this a more accurate way to prepare for alternative payment models? *J Orthop Trauma* 2018;32:344-8.
19. Fang C, Pagani N, Gordon M, et al. Episode-of-care costs for revision total joint arthroplasties by decadal age groups. *Geriatrics (Basel)* 2021;6:49.
20. Fang CJ, Shaker J, Drew J, et al. The cost of hip and knee revision arthroplasty by diagnosis-related groups: comparing time-driven activity-based costing and traditional accounting. *J Arthroplasty* 2021;36:2674-9.
21. Vendittoli PA, Pellei K, Desmeules F, et al. Enhanced recovery short-stay hip and knee joint replacement program improves patients outcomes while reducing hospital costs. *Orthop Traumatol Surg Res* 2019;105:1237-43.
22. *Rémunération à l'acte*. Québec: Régie de l'assurance maladie; 2021. Available: <https://www.ramq.gouv.qc.ca/fr/professionnels/medecins-specialistes/manuels/Pages/remuneration-acte.aspx> (accessed 2022 Feb. 1).
23. Wu XD, Zhu Z, Xiao P, et al. Are routine postoperative laboratory tests necessary after primary total hip arthroplasty? *J Arthroplasty* 2020;35:2892-8.
24. Halawi MJ, Plourde JM, Cote MP. Routine postoperative laboratory tests are not necessary after primary total hip arthroplasty. *J Arthroplasty* 2019;34:3538-41.
25. Rudy MD, Bentley J, Ahuja N, et al. Determinants of cost variation in total hip and knee arthroplasty: implications for alternative payment models. *J Am Acad Orthop Surg* 2020;28:e-245-54.
26. Maradit Kremers H, Visscher S, Kremers W, et al. Obesity increases length of stay and direct medical costs in total hip arthroplasty. *Clin Orthop Relat Res* 2014;472:1232-9.
27. Petis SM, Howard JL, Lanting BA, et al. In-hospital cost analysis of total hip arthroplasty: Does surgical approach matter? *J Arthroplasty* 2016;31:53-8.
28. DiGioia AM, Greenhouse PK, Giarrusso ML, et al. Determining the true cost to deliver total hip and knee arthroplasty over the full cycle of care: preparing for bundling and reference-based pricing. *J Arthroplasty* 2016;31:1-6.
29. Bertin KC. Minimally invasive outpatient total hip arthroplasty: a financial analysis. *Clin Orthop Relat Res* 2005;435:154-63.
30. Aynardi M, Post Z, Ong A, et al. Outpatient surgery as a means of cost reduction in total hip arthroplasty: a case-control study. *HSS J* 2014;10:252-5.